Adicet Bio, Inc. a leading biotechnology firm specializing in the discovery and development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, recently unveiled groundbreaking preclinical data in support of its IND readiness for ADI-270. This exciting news was presented through an oral presentation during the prestigious American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting.
The comprehensive abstract details new preclinical information about ADI-270, a fortified allogeneic off-the-shelf gamma delta CAR (chimeric antigen receptor) T cell therapy candidate aimed at CD70-positive cancers. The significance of this development is underlined by its selection for an oral presentation at this prestigious meeting, which draws the best minds in the gene and cell therapy sectors worldwide.
The therapeutic candidate, ADI-270, is an innovation in oncological treatment, pioneering the concept of an armored CAR T-cell therapy. This feature facilitates the therapy’s resistance against the patient’s immune system possibly leading to more successful long-term results.
Headquartered in Redwood City, California, and with offices in Boston, Adicet Bio focuses on developing therapies that capitalize on the unique properties of gamma delta T cells. These immune cells have shown promise in treating a range of CD70 positive cancers, prevalent forms of cancer with troubled clinics globally. The reveal of ADI-270’s IND readiness at the ASGCT meeting reinforces Adicet’s commitment to driving forward the potential applications of these cells within the oncology field.
This reveal comes alongside news of continued financial growth at Adicet Bio, with their corporate associates and revenue streams solidifying their position within the biotechnology and pharmaceutical industry further. As one of the vanguards in this field, Adicet Bio continues to navigate the frontiers of gene and cell therapy for autoimmune diseases and cancer, and the readiness of ADI-270 for IND application provides further evidence of this commitment.
However, the journey for ADI-270 does not end here. Adicet Bio, thorough its keen scientific acumen and business prowess, will continue to explore and develop its groundbreaking T-cell therapy’s potential that carries high expectations- a ray of hope for individuals across the globe battling with CD70 positive cancers.
Comments